Biotech Values

[ghmm]

InterMune 2009 8-12 Canaccord Adams Presentation Notes
(just new info, Q2 call was week before has more info)

HCV
. 3 presentations at AASLD. Data from all 7 cohorts will be presented.
. If ritonavir boosting study positive could amend Phase 2B to incorporate into dosing.

Pirfenidone
. Expect panel meeting in Spring ‘10
. Again continued to emphasize consistency with Shionogi Phase 3 (and mention Phase 2). Consistency among trials and the lower dose will be a key focus in arguing for benefit of drug. No reason seen for placebo divergence in Capacity one trial beginning around week 48.
. Seem to be looking more at 6 minute walk